BEIJING, 2015-07-28 04:14 CEST (GLOBE NEWSWIRE) -- Yabao Pharmaceutical Co,
Inc. (Shanghai Stock Exchange 600351), a leading pharmaceutical company in
China, today announced that it entered into an exclusive license with Lawson
Health Research Institute (Lawson) to discover, develop and commercialize
products based on annexin A5 for the treatment of sepsis in July 2014, and that
by this month it has successfully completed discovery validation work and moved
the program into preclinical development. The use of annexin A5 to treat sepsis
was discovered by a team led by Dr. Qingping Feng, a scientist at Lawson and
Western University.

Under the terms of the agreement, Yabao receives exclusive rights to discover,
develop and commercialize in China, Taiwan and Hong Kong, while Lawson retains
rights in all other markets. Financial terms were not disclosed.

“Yabao is pleased to collaborate with Lawson, a leading Canadian research
institute focused on improving the lives of patients through medical discovery.
Yabao is also very pleased that the program has been moving very smoothly,
showing great potential as a novel drug candidate for a huge unmet medical
need," commented Dr. Peng Wang, President R&D, Yabao Pharmaceutical Co., "This
opportunity for Yabao to further develop leading research into innovative
products is further evidence of Yabao's growing commitment to partner the best
science to treat serious diseases in China."

“Our partnership with Yabao is proving to be very productive for progressing
annexin A5 into clinical development and we are highly encouraged by the
results to date,” commented Kirk Brown, Manager, Business Development, Lawson
Health Research Institute. “Lawson is committed to the translation of health
care discoveries from lab bench to patient bedside. To that end Lawson is
pleased to collaborate with Yabao, a leading Chinese pharmaceutical company
with strong drug development capabilities, to develop this promising new drug
for the treatment of sepsis, one of the leading causes of death globally,”
commented Dr. David Hill, Scientific Director, Lawson Health Research
Institute.

About Yabao
Pharmaceutical Co.

Yabao Pharmaceutical Co. (Shanghai Stock Exchange 600351) is a leading China
pharmaceutical company with fully-integrated development, manufacturing, and
commercialization in China. Yabao is recently pursuing strategic development of
innovative pharmaceuticals in addition to Yabao's well-established business in
modern traditional Chinese medicines and chemical generics. In addition to
strong clinical and regulatory capabilities, Yabao has strong capabilities in
formulation and API production and meets good manufacturing practice (cGMP)
requirements with two manufacturing sites approved by US FDA and European
agency, respectively. For more information about Yabao Pharmaceutical Co.,
please visit www.yabao.com.cn

Contact
Name: Ms. Weina Liu
Phone: +86-10-5808-6285
Email: liuweina@yabaoyaoye.com

About Lawson Health
Research Institute

Lawson Health Research Institute is the research institute of London Health
Sciences Centre and St. Joseph's Health Care London. Working in partnership
with Western University, Lawson Health Research Institute is committed to
furthering scientific knowledge to advance health care around the world.
www.lawsonresearch.com. Commercialization at Lawson is facilitated by
WORLDiscoveries®, a joint venture of Lawson, Western University and Robart’s
Research Institute, the first Canadian technology transfer venture to open
permanent satellite offices in China.

Contact
Name: Julia Capaldi
Phone: 519-685-8500 ext. 75616
Email: julia.capaldi@lawsonresearch.com